# US 2023/0390145 A1 · Compression device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0390145 A1
- Document ID: US20230390145A1
- Status: Published application
- Kind: A1
- Application number: 18/250,797
- Filed: 2021-10-27
- Published: 2023-12-07
- Earliest claimed: 2020-10-27
- Assignees: National University of Ireland, Galway
- Applicants: National University of Ireland, Galway
- Inventors: Aaron HANNON; Bárbara OLIVEIRA; Martin O'HALLORAN
- Web page: https://patentgrep.com/patent/US20230390145A1

## CPC

- A61H 9/0078: {with intermittent or alternately inflated bladders or cuffs (mattresses for preventing bed-sores with alternated pressurized chambers A61G7/05776)}
- A61B 5/0261: {using optical means, e.g. infrared light}
- A61B 5/4836: {Diagnosis combined with treatment in closed-loop systems or methods (A61B5/0036 takes precedence)}
- A61B 5/6803: {Head-worn items, e.g. helmets, masks, headphones or goggles}
- A61H 2201/165: Wearable interfaces
- A61H 2201/5071: Pressure sensors
- A61H 2205/021: Scalp
- A61H 2205/065: Hands
- A61H 2205/12: Feet
- A61H: PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY (electrotherapy, magnetotherapy, radiation therapy or ultrasound therapy A61N)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

A medical device comprising a bladder (or plurality of bladders), an attachment mechanism, a fluid inlet, a fluid outlet, a compressor, a pressure regulator system, and a perfusion sensor, which is compressed against intact tissue (unbroken skin or surface tissue in a cavity) for the purpose of minimising blood perfusion to prevent drug delivery to a non-target site.

## Claims

### Claim 1

A pneumatic compression device (1,100) for use in preventing or treating chemotherapy-induced alopecia or chemotherapy-induced peripheral neuropathy (CIPN) in a subject receiving chemotherapy treatment, the device (1,100) comprising: an attachment member (2), a first layer (3) connected to the attachment member (2), at least one primary bladder (5); and a fluid inlet (12), wherein the at least one primary bladder (5) is configured to inflate with a fluid at ambient temperature, and which exerts a compressive pressure to the non-treated area of the subject when the bladder (5) is inflated minimising blood perfusion to prevent chemotherapy delivery to the non-treated area.

### Claim 2 (depends on 1)

The pneumatic compression device (1) of claim 1, further comprising a second layer (4) and an outer mesh layer (6) surrounding the second layer (4).

### Claim 3 (depends on 1, 2)

The pneumatic compression device (1) of claim 1 or claim 2, further comprising an inner membrane (7), the inner membrane (7) forms an inner lining of the device (1), nestling between the second layer (4) and the tissue of the subject.

### Claim 4

The pneumatic compression device of any one of the preceding claims, further comprising a secondary bladder (11), wherein the secondary bladder (11) is configured to attach to the attachment member (2) such that the secondary bladder (11) comes in contact with the tissue of the subject.

### Claim 5

The pneumatic compression device (1) of any one of the preceding claims, further comprising a first fastening system (16) configured to prevent the outward movement of the outer mesh layer (6).

### Claim 6 (depends on 5)

The pneumatic compression device (1) of claim 5, further comprising a second fastening system (17) adapted to tighten the attachment member (2) to the subject.

### Claim 7 (depends on 2, 3, 4, 5, 6)

The pneumatic compression device (1) of any one of claims 2 to 6, wherein the at least one primary bladder (5) is attached along its inner edge (5a) to the second layer (4), and along its perimeter surface (5b) to the first layer (3) and along its lower edge surface (5c) to the attachment member (2).

### Claim 8

The pneumatic compression device (1) of any one of the preceding claims, further comprising at least one adjustable strap (10) to secure the device (1) under, around or over the chin of the subject.

### Claim 9 (depends on 1)

The pneumatic compression device (100) of claim 1, wherein the at least one primary bladder (5) is configured to have a plurality of sockets (108) to accommodate the fingers of the hand or the toes of the foot of the subject.

### Claim 10 (depends on 1, 9)

The pneumatic compression device (100) of claim 1 or claim 9, wherein the at least one primary bladder (5) is configured to be a single socket that accommodates the whole hand or the foot of the subject.

### Claim 11 (depends on 1, 9, 10)

The pneumatic compression device (100) of any one of claim 1, 9 or 10, further comprising a first securing member (102) to secure the device (100) in place.

### Claim 12 (depends on 1, 9, 10, 11)

The pneumatic compression device (100) of any one of claim 1, 9, 10 or 11, further comprising a second securing member (103) to secure the device (100) in place.

### Claim 13

The pneumatic compression device (1,100) of any one of the preceding claims, wherein the attachment member (2), the first fastening system (16), second fastening system (17), the first securing member (102), or the second securing member (103) can be used with greater force to tighten the device (1,100) against the surface of the scalp, foot, or hand through a drawstring mechanism.

### Claim 14

A pneumatic compression device (200) for use in preventing or treating chemotherapy-induced infertility in a subject receiving chemotherapy treatment, the device (200) comprising: at least one primary bladder (205), an applicator (202) adapted to accommodate the at least one primary bladder (205), and a cap (204) configured to contain the at least one primary bladder (205) within the applicator (202) when deflated, wherein the at least one primary bladder (205) located within the applicator (202) is configured to inflate with air or a gas at ambient temperature, and which exerts a compressive pressure when the bladder (205) is inflated.

### Claim 15 (depends on 14)

The pneumatic compression device (200) of claim 14, further comprising an outer shell (210) and an inner shell (212), which combine to form an enclosure (214) that accommodates the at least one primary bladder (205).

### Claim 16 (depends on 14, 15)

The pneumatic compression device (200) of claim 14 or claim 15, further comprising a support means (208) housed internally in the applicator (202) and in communication with the cap (204).

### Claim 17 (depends on 16)

The pneumatic compression device (200) of claim 16, wherein the support means (208) is surrounded by the at least one primary bladder (205).

### Claim 18 (depends on 14, 15, 16, 17)

The pneumatic compression device (200) of any one of claims 14 to 17, wherein the cap (204) is reversibly connected to the applicator (202) and is released from the applicator (202) when the at least one primary bladder (205) is inflated.

### Claim 19 (depends on 14, 15, 16, 17)

The pneumatic compression device (200) of any one of claims 14 to 17, wherein the cap (204) is fixed to the applicator (202) and further comprises an aperture (206) through which the at least one primary bladder (205) is pushed through prior to inflation.

### Claim 20

The pneumatic compression device (1,100,200) of the preceding claims, further comprising a control element (9).

### Claim 21 (depends on 20)

The pneumatic compression device (1,100,200) of claim 20, wherein the control element (9) comprises a pump, a pressure sensor, and a tissue perfusion sensor.

### Claim 22 (depends on 21)

The pneumatic compression device (1,100,200) of claim 21, wherein the pressure sensor is in communication with the at least one primary bladder (5,205).

### Claim 23

The pneumatic compression (1,100,200) device of any one of the preceding claims, wherein the at least one primary bladder (5,205) further comprises a plurality of bladder compartments, each bladder compartment operating independently of each other.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The pneumatic compression device (1,100,200) of any one of claims 1 to 22, wherein the at least one primary bladder (5,205) further comprises a plurality of bladder compartments, each of the plurality of bladder compartments are in fluid communication with a bladder compartment juxtaposed it.

### Claim 25 (depends on 23, 24)

The pneumatic compression device (1,100,200) of claim 23 or claim 24, wherein the at least one primary bladder (5,205) or the plurality of bladder compartments are connected to the pump, the pump having a two-way valve system to control the inflow and outflow of the fluid.

### Claim 26

The pneumatic compression device (1,100,200) of any one of the preceding claims, wherein when activated, the device (1,100,200) applies a compressive pressure of between about 20 mmHg to about 100 mmHg to the subject.

### Claim 27 (depends on 26)

The pneumatic compression device (1,100,200) of claim 26, wherein the compressive pressure being applied is between about 25 mmHg and about 75 mmHg.

### Claim 28 (depends on 26, 27)

The pneumatic compression device (1,100,200) of claim 26 or claim 27, wherein the compressive pressure being applied is between about 40 mmHg and about 60 mmHg.

### Claim 29

The pneumatic compression device (1,100,200) of any one of the preceding claims, wherein the compressive pressure is applied incrementally.

### Claim 30 (depends on 29)

The pneumatic compression device (1,100,200) of claim 29, wherein the compressive pressure is applied uniformly and/or non-uniformly.

### Claim 31

The pneumatic compression device (1,100,200) of any one of the preceding claims, further comprising a foam layer inserted within the at least one primary bladder (5,205) or one or more of the plurality of bladders; wherein the foam layer exerts a reaction force through the bladder onto the scalp, foot, hand, or within a cavity when air is withdrawn incrementally creating a vacuum inside the at least one primary bladder (5,205) or one or more of the plurality of bladders.

### Claim 32

The pneumatic compression device (1,100) according to any one of the preceding claims, wherein a fluid or a solid which is viscous at ambient pressure and a solid form at pressures lower than atmospheric pressure, is inserted into the at least one primary bladder (5) or one or more of the plurality of bladders, wherein when pressure within the at least one primary bladder (5) decreases, the fluid or the sold hardens, creating a modifiable compressive force against the tissue.

### Claim 33

The pneumatic compression device (1,100,200) of any one of the preceding claims, wherein the at least one primary bladder (5,205) or the plurality of bladders, are inflated are to a pre-determined pressure level below the target therapeutic pressure level prior to the user using the device (1,100,200).

### Claim 34

The pneumatic compression device (1,100,200) of any one of the preceding claims, wherein the at least one primary bladder (5,205) or the plurality of bladders are provided at a pre-determined pressure level and are not further inflated.

### Claim 35

The pneumatic compression device (1,100,200) of any one of the preceding claims, wherein the attachment member (2) further comprises at least one status indicator light (13).

### Claim 36

A method of controlling drug delivery via the blood vessels to a target site on the body, the method comprising:
mechanically compressing the skin/surface tissue at a target tissue site at a predetermined compressive force to occlude the upstream blood vessels;
maintaining the compressive force for a predetermined period; and
releasing the compressive force applied to the tissue at the target site at a pre-determined rate and in a pre-determined geometric pattern.

### Claim 37 (depends on 36)

The method of claim 36, wherein the compressive force is applied to the tissue site upstream of the intended effect site.

### Claim 38 (depends on 36, 37)

The method of claim 36 or claim 37, wherein the compressive force is applied to the skin/surface tissue at the target site at about 20 mmHg to about 100 mmHg.

### Claim 39 (depends on 36, 37, 38)

The method of any one of claims 36 to 38, wherein the compressive force applied is configured to mechanically occlude the microvasculature close to the surface of the tissue and local arterial supply vessels.

### Claim 40 (depends on 36, 37, 38, 39)

The method of any one of claims 36 to 39, wherein the compressive pressure is applied uniformly across the tissue site to be treated.

### Claim 41 (depends on 36, 37, 38, 39, 40)

The method of any one of claims 36 to 40, wherein the compressive force is maintained for a period of between 30 minutes and 7 hours.

### Claim 42 (depends on 36, 37, 38, 39, 40, 41)

The method of any one of claims 36 to 41, wherein the compressive force is applied at different areas of the tissue.

### Claim 43 (depends on 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 36 to 42, wherein the compressive force is applied in a pulsatile fashion.

### Claim 44

A method of controlling drug delivery to a target site on the body, followed by a period of reactivating blood flow to ensure long-term tissue viability, the method, comprising:
mechanically compressing the skin/surface tissue at the target site with a predetermined compressive force to cause occlusion of the local microvasculature;
maintaining microvasculature occlusion for a predetermined period of time such that drugs circulating through the vascular system do not reach the target site or site downstream of the target site;
releasing the occlusion in a controlled manner at a pre-determined rate and in a pre-determined geometric pattern;
sensing a physiological parameter;
adjusting the mechanical compression applied to the tissue site based on the sensed physiological parameter; and
applying compressive forces in a pulsatile fashion against the skin tissue to promote blood flow allowing waste agents to be removed from the local vasculature.

### Claim 45 (depends on 44)

The method of claim 44, wherein the sensed physiological parameter is the blood perfusion in the tissue site being treated.
